Dear Readers, We want to let you know about some recent changes to manuscript formats and guidelines that have been made at Clinical Cancer Research (CCR). First, we have made some changes to how research articles are categorized. We now accept submission of research articles in the following four categories: Cancer Therapy: Clinical; Personalized Medicine and Imaging; Cancer Therapy: Preclinical; and Biology of Human Tumors. Updated guidelines and descriptions for these categories can be found in the Instructions for Authors section of the journal website (http:// clincancerres.aacrjournals.org/site/misc/journal_ifora.xhtml). These new guidelines emphasize that studies submitted to CCR should be highly novel and have a clear translational impact. They also describe the level of rigor with which research submitted to CCR is evaluated (for example, biomarker studies should be definitive in size and statistical power, and preclinical studies should use multiple in vitro/in vivo models). We strongly encourage authors to review these guidelines in full to determine if their study will be a good fit for the journal.
In addition, we are planning to introduce a new format for manuscripts reporting clinical trials, called the Clinical Trial Brief Report. This will be the suggested format for trials of novel agents, combination treatments, or indications that contain limited correlative science but report initial findings with an extraordinary degree of clinical activity. In contrast, we typically look for accompanying pharmacokinetic, pharmacodynamic, and/or pharmacogenetic data in clinical trial manuscripts submitted as full-length research articles. As the name implies, the Clinical Trial Brief Report will be shorter in format than a standard-length research article (we expect it will be limited to 2,500 words and four figures or tables). Also, manuscripts submitted as a Clinical Trial Brief Report may be selected for an expedited review at the discretion of the editors. At this time the Clinical Trial Brief Report format is planned only for manuscripts describing clinical trials; other types of original research studies should continue to be submitted as standard research articles.
We feel that these updated guidelines and table of contents sections better reflect the priorities of CCR, and we hope they will provide authors with guidance about how submitted studies are evaluated. As we approach the twentieth anniversary of CCR in 2015, which will be commemorated with special content published throughout the year, we are excited about the future of the journal and will continue to ensure it remains a vital forum for publishing cutting-edge translational and clinical research. 
